Francisco José Romeo

Francisco José Romeo

Auto-generated profile, based on publicly available information

Francisco José Romeo

Division of Cardiology, University of Miami Miller School of Medicine/Jackson Memorial Hospital, Miami, Florida

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in JACC
Verified
Journal Article
Closed access
JTJuan Torrado
Juan Torrado
CCChad Cain
Chad Cain
AMAdolfo G. Mauro
Adolfo G. Mauro
FRFrancisco Romeo
Francisco Romeo
RORamzi Ockaili
Ramzi Ockaili
FSFadi N. Salloum
Fadi N. Salloum

31 July 2017 in ESC Heart Failure
Verified
Journal Article
Open access
PDF file
ISIgnacio M. Seropian
Ignacio M. Seropian
FRFrancisco J. Romeo
Francisco J. Romeo
RPRodolfo Pizarro
Rodolfo Pizarro
NVNorberto O. Vulcano
Norberto O. Vulcano
RPRicardo A. Posatini
Ricardo A. Posatini
CBCesar A. Belziti
Cesar A. Belziti
Aims The aim of this study was to evaluate whether neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) predict outcome in heart failure (HF) patients undergoing heart transplantation (HTX). Methods and results Data from 111 HF patients undergoing HTX 2010–2015 were retrospectively reviewed. NLR and PLR were calculated before HTX, immediately after HTX, and at 6 and 24 hours. Primary endpoint was in-hospital mortality, and secondary endpoints were 1 year mortality and renal replacement therapy (RRT). Prognostic factors were assessed by multivariate analysis, and the predictive values of NLR and PLR for mortality were compared. The discriminatory performance for predicting in-hospital mortality was better for NLR [area under the receiver operating characteristic curve (AUC) = 0.644, 95% confidence interval 0.492–0.797] than for PLR (AUC = 0.599, 95% confidence interval 0.423–0.776). Best cut-off value was 2.41 for NLR (sensitivity 86%, specificity 67%) and 92.5 for PLR (sensitivity 86%, specificity 68%). When divided according to best cut-off value, in-hospital mortality was significantly higher in the high NLR group (17.5% vs. 3.2%, P < 0.05), but not in the high PLR group (16.5% vs. 6.3%, P = ns). One year mortality was not significantly higher for either group (37.5% vs. 6.5% for NLR; 36.7% vs. 9.4% for PLR, P = ns for both), while RRT was significantly higher in both the NLR and PLR high groups (33.8% vs. 0%; 32.9% vs. 3.1%, respectively, P < 0.001). Multivariate analysis indicated that only high NLR (hazard ratio = 3.403, P < 0.05) and pre-transplant diabetes (hazard ratio = 3.364, P < 0.05) were independent prognostic factors for 1 year mortality. Conclusions High NLR was a predictor for in-hospital mortality, and an independent prognostic factor for 1 year mortality. Both high NLR and high PLR were predictors for RRT.

27 May 2021 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
FRFrancisco José Romeo
Francisco José Romeo
JCJuan Guido Chiabrando
Juan Guido Chiabrando
ISIgnacio Miguel Seropian
Ignacio Miguel Seropian
JRJuan Valle Raleigh
Juan Valle Raleigh
HCHoracio Medina de Chazal
Horacio Medina de Chazal
DBDaniel Horacio Berrocal
Daniel Horacio Berrocal

1 June 2018 in Transplantation Proceedings
Verified
Journal Article
Closed access
FRF.J. Romeo
F.J. Romeo
CVC.F. Varela
C.F. Varela
NVN. Vulcano
N. Vulcano
RPR. Pizarro
R. Pizarro
GGG. Greloni
G. Greloni
CBC.A. Belziti
C.A. Belziti

11 April 2023 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
ARAnjali J. Ravichandran
Anjali J. Ravichandran
FRFrancisco J. Romeo
Francisco J. Romeo
RMRenata Mazurek
Renata Mazurek
Kiyo IshikawaKiyo Ishikawa
Kiyo Ishikawa

13 August 2021 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
BNBharat Narasimhan
Bharat Narasimhan
HNHarish Narasimhan
Harish Narasimhan
MLMarta Lorente-Ros
Marta Lorente-Ros
FRFrancisco Jose Romeo
Francisco Jose Romeo
KBKirtipal Bhatia
Kirtipal Bhatia
Wilbert AronowWilbert Aronow
Wilbert Aronow
Despite tremendous advances, the shortcomings of current therapies for coronary disease are evidenced by the fact that it remains the leading cause of death in many parts of the world. There is hen...